Samsung Bioepis acquires domestic product approval of ‘Renflexis’
Samsung Bioepis announced acquisition of product approval of Renflexis(Remicade biosimilar), an autoimmune disease treatment, from the Ministry of Food and Drug Safety on the 4th.
Thus, Samsung Bioepis has become a company owning two autoimmune disease treating biosimilars along with Brenzys app...
Fees
- Email service daily and homepage access.
- $300 per month. ($3,240 per year)
- 5 Email holders per each company.
- Anual contract base.
